JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

Search

Charles River Laboratories International Inc

Cerrado

SectorSalud

216.82 -1.27

Resumen

Variación precio

24h

Actual

Mínimo

213.55

Máximo

217.74

Métricas clave

By Trading Economics

Ingresos

2.9M

56M

Ventas

-27M

1B

BPA

2.43

Margen de beneficio

5.529

Empleados

18,700

EBITDA

-23M

198M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+0.92% upside

Dividendos

By Dow Jones

Próximas Ganancias

18 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.1B

11B

Apertura anterior

218.09

Cierre anterior

216.82

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 ene 2026, 23:51 UTC

Ganancias

Correction to Samsung Fourth-Quarter Net Profit Article

28 ene 2026, 23:49 UTC

Acciones populares

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 ene 2026, 23:19 UTC

Ganancias

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 ene 2026, 22:43 UTC

Ganancias

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 ene 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 ene 2026, 23:30 UTC

Charlas de Mercado

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 ene 2026, 23:28 UTC

Ganancias

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 ene 2026, 23:26 UTC

Ganancias

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 ene 2026, 23:21 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 23:18 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:58 UTC

Ganancias

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:48 UTC

Charlas de Mercado

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 ene 2026, 22:45 UTC

Ganancias

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 ene 2026, 22:44 UTC

Ganancias

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 ene 2026, 22:43 UTC

Ganancias

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 ene 2026, 22:41 UTC

Ganancias
Acciones populares

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 ene 2026, 22:41 UTC

Charlas de Mercado

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 ene 2026, 22:41 UTC

Ganancias

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 ene 2026, 22:40 UTC

Ganancias

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 ene 2026, 22:39 UTC

Ganancias

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 ene 2026, 22:38 UTC

Ganancias

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 ene 2026, 22:37 UTC

Ganancias

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 ene 2026, 22:35 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 22:26 UTC

Charlas de Mercado
Ganancias

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Comparación entre iguales

Cambio de precio

Charles River Laboratories International Inc Esperado

Precio Objetivo

By TipRanks

0.92% repunte

Estimación a 12 meses

Media 221.55 USD  0.92%

Máximo 265 USD

Mínimo 170 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Charles River Laboratories International Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

9

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

117.16 / 144.77Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat